DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21), FiscalAI reports.
DiaMedica Therapeutics Price Performance
DiaMedica Therapeutics stock traded down $0.30 during midday trading on Friday, reaching $9.03. The stock had a trading volume of 133,080 shares, compared to its average volume of 201,021. The firm’s fifty day simple moving average is $8.16 and its two-hundred day simple moving average is $7.20. DiaMedica Therapeutics has a twelve month low of $5.24 and a twelve month high of $11.00. The firm has a market cap of $486.72 million, a price-to-earnings ratio of -12.53 and a beta of 0.95.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on DMAC shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen raised DiaMedica Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, DiaMedica Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $12.00.
View Our Latest Stock Analysis on DMAC
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.
Featured Stories
- Five stocks we like better than DiaMedica Therapeutics
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
